Amanta Healthcare Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-06-16
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Standalone
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Only standalone filings are available for this company.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 65 Cr | 71 Cr | 74 Cr | 77 Cr |
| Operating expenses (approx.) | 49 Cr | 59 Cr | 58 Cr | 60 Cr |
| EBITDA | 16 Cr | 12 Cr | 16 Cr | 17 Cr |
| OPM % | 24.3% | 17.1% | 21.5% | 21.6% |
| Other income | 0.96 Cr | 0.07 Cr | 0.68 Cr | 2 Cr |
| Interest | 6 Cr | 5 Cr | 5 Cr | 4 Cr |
| Depreciation | 5 Cr | 5 Cr | 5 Cr | 5 Cr |
| Profit before tax | 5 Cr | 2 Cr | 6 Cr | 8 Cr |
| Tax % | 28.8% | 47.0% | 26.6% | 27.4% |
| Net profit | 4 Cr | 1 Cr | 5 Cr | 6 Cr |
| EPS (₹) | ₹1.22 | ₹0.35 | ₹1.35 | ₹1.61 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 288 Cr | Sign in for TTM |
| Operating expenses (approx.) | 227 Cr | Sign in for TTM |
| EBITDA | 61 Cr | Sign in for TTM |
| OPM % | 21.1% | Sign in for TTM |
| Other income | 3 Cr | Sign in for TTM |
| Interest | 21 Cr | Sign in for TTM |
| Depreciation | 19 Cr | Sign in for TTM |
| Profit before tax | 21 Cr | Sign in for TTM |
| Tax % | 29.6% | Sign in for TTM |
| Net profit | 15 Cr | Sign in for TTM |
| EPS (₹) | ₹4.33 | Sign in for TTM |
| Dividend payout % | 2.7% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 39 Cr |
| Reserves | 181 Cr |
| Borrowings | 72 Cr |
| Other liabilities | 265 Cr |
| Total liabilities | 558 Cr |
| Fixed assets (net) | 197 Cr |
| CWIP | 82 Cr |
| Investments | 7 Cr |
| Other assets | 238 Cr |
| Total assets | 558 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | 48 Cr |
| Cash from investing | -94 Cr |
| Cash from financing | 126 Cr |
| Net cash flow | 81 Cr |
| Free cash flow (OCF − Capex) | -32 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2026 |
|---|---|
| ROCE % | 14.3% |
| ROE % | 6.8% |
| Debtor days | — |
| Inventory days | 311 |
| Days payable | — |
| Cash conversion cycle | 311 |
| Debt / equity | 0.33 |
| Current ratio | 1.69 |
| Net debt / EBITDA | -0.14 |
Compare with peers
Loading peers…